I am a High Net-Worth Individual
o2h Ventures Limited has launched the first fund in the UK solely focused on early stage biotech therapeutic and related AI opportunities in the UK. The geographic scope shall be UK wide but will target the growing Cambridge biotech cluster. The fund is structured to be S/EIS compliant providing income, inheritance and capital gains tax breaks for UK tax payers.
A shift in focus of the large pharmaceutical companies from developing innovation in-house to acquiring innovation externally increased demand for the best science providing earlier exit options. The fund is headquartered in the o2h SciTech Park, Cambridge, where it can provide the incubation and support as part of a community to the companies it has invested in to help them achieve a critical value inflexion point. The team at o2h have access to some of the most exciting ideas through its live grass roots working relationships fostered with entrepreneurs and scientists over many years.
For more information email us at- email@example.com
If you would like further details and would like to read our full Information Memorandum you can request to download it below:
You invest £50k
EIS gives you £15k tax relief from HMRC
SEIS gives you £25k tax relief from HMRC
Investment now worth £100k
income tax relief £15k
performance incentive £10k
net profit £55k
Investment still worth £50k
income tax relief £15k
performance incentive £0
net profit £15k
Investment now worth £0
income tax relief £15k
loss relief £15,750 *
performance incentive £0
capital loss £19,250
* Loss relief calculated on higher rate tax bracket Worked example is net of any fund fees
A chemist with a passion for drug discovery and programme management. >17 years of experience working with various research organisation like Alembic, Evotec, o2h and Piramal. He gained his PhD from India and post-doctoral experience from Glasgow University, UK. Tejas visits many of the biotech conferences, pitching events, tech transfer offices as well as managing live working relationships with biotech companies to find discovery opportunities to evaluate.
Archa is associated with o2h for over 3 years now. She is one of the most valuable resources of o2h and plays the crucial role of onboarding manager in o2h ventures by profusely guiding investors to smoothly get along with the investment processes and other necessary formalities. Archa has a Bachelor’s degree in Computer Engineering She is the core member of o2h technology products including Visibly and Chemistry in the Cloud.
R G Boyle is a founder and the CEO of Sentinel Oncology Ltd, a company dedicated towards the discovery of novel small molecules for the treatment of unmet medical needs. Robert is a medicinal chemist by background with over twenty-five years’ industrial experience. He has held positions at Pfizer (1993-1997); Cambridge Discovery Chemistry (1997-2000); Millennium Pharmaceuticals (200-2003); Astex Therapeutics (2003-2005) & Sentinel Oncology (2005-present). As CEO & founder of Sentinel Oncology, he has successfully raised multiple rounds of funding, built a pipeline of small molecule drug assets and secured multiple licensing deals with Biotech and Pharma. Sentinel has been the recipient of numerous awards & grants for innovation and Robert is a named inventor on over 50 patents & publications describing the discovery and use of small molecules for the treatment of unmet medical needs.
Sam is a graduate of Robinson College Cambridge, a PWC qualified Chartered Accountant and an investment banking veteran with 25 years of experience in Equities and other advisory roles. He has worked at Robert/Jardine Fleming, JP Morgan, Cazenove, UBS, Seymour Pierce, Standard Chartered and most recently Credit Suisse. He has a track record of successful public and private fund raising and has built up an extensive set of deep institutional relationships in the UK and Asia.
Large pharmaceutical companies have been closing down research centres globally for the last decade. This shift in focus of the large pharmaceutical companies has moved them from developing innovation in-house to acquiring innovation externally, forcing us prices for the best science and providing earlier exit opportunities. The team at o2h have access to the most exciting scientific ideas in the through its live working relationships fostered over many years working as a discovery services company giving it far earlier access than competitors to the most promising companies. Early stage companies often need more than just money, o2h Ventures has built a unique integrated model for early stage companies which includes the possibility of offering company’s incubation in its O2h SciTech Park, in Cambridge, UK, and/or the option to jump-start their research activity from o2h Discovery in Ahmedabad, India. The fund is structures to be (S)EIS compliant proving generous income, Inheritance and capital gains tax for UK tax payers.
(made personally by the Fund Managers)
Cambridge, UK, 01 April 2019: Metrion Biosciences Ltd (“Metrion”), the specialist ion channel contract research and drug discovery company, announced today that it has completed a fully subscribed funding round on 14 March. Metrion will use the funds to support the broadening of its ion channel screening capabilities, and continued research into novel Kv1.3 inhibitors for the treatment of auto-immune conditions.
Cambridge, UK, 28 March 2019. The o2h Therapeutics Fund & AI (“The Fund”), an early stage S/EIS fund investing in biotechnology therapeutic and related AI opportunities, is pleased to announce an investment in Exonate, an early stage biotechnology company.
We are grateful to our early investors of The o2h Therapeutics and AI EIS Fund and should they wish to increase their participation in the upcoming deals we have put forward an offer for them to invest before the end of the tax year on April 5th with a 50% reduction in the initial fee from 4% to 2%.
we are unable to follow anyone. Is it a bug from your end? I do not see my account has been suspended or blocked.… https://t.co/N7F4vnIs3M
RT @BiotechJon: I note that o2h Therapeutics fund have announced participation in Exonate, Stemnovate and Metrion's recent financings. Cong…
We are proud to be a supporter for the T-20 Cricket in St. Kitts match between England and West Indies recently. At… https://t.co/7swGOf95Fs
We are pleased to welcome both o2h Ventures Therapeutics Fund as a new shareholder and Sunil Shah, Managing Partner… https://t.co/txSRsvEMta
Delighted to attended Fragments 19 where o2h Discovery presented its proprietary fragment library that can help ide… https://t.co/qFEntuhp2l
RT @Riddhi_16: @CygnetInfotech’s Dr. Nilesh Modi echoed the ethos ‘IT is about You’ at @O2hVentures #Innovation Conference quoting, @Andrew…
The o2h Therapeutics and AI Fund makes investment in early stage biotechnology company @ExonateUK -… https://t.co/F4iV7xGuUl
RT @GBIMagazine: o2h Ventures is raising a therapeutics fund to invest into early stage innovations with a view to license, or sell to larg…